Abstract

20
Precision medicine might be the response to the recent questioning of the use of metformin as an 21 anticancer drug in colorectal cancer (CRC). Thus, in order to establish properly its benefits, its 22 application need to be assayed on the different progression stages of CRC. In this way, organoids 23 imply a more physiological tool, representing a new therapeutic opportunity for CRC 24 personalized treatment to assay tumor stage-dependent drugs effects. Since the lipid metabolism-25 related axis, ACSL/SCD, stimulates colon cancer progression and Metformin is able to rescuing 26 the invasive and migratory phenotype conferred to cancer cells upon this axis overexpression; we 27 checked ACSL/SCD status, its regulatory miRNAs and the effect of Metformin treatment in 28 organoids as a model for specific and personalized treatment. Despite ACSL4 expression is 29 upregulated in CRC-like organoids, Metformin is able to downregulate it, especially in the first 30 stages. Besides, organoids are clearly more sensitive in this first stage (Apc mutated) to 31 Metformin than current chemotherapeutic drugs such as fluorouracil (5-FU). Metformin performs 32 an independent "Warburg effect" blockade to cancer progression and is able to reduce crypt stem 33 cell markers expression such as Lgr5+. These results suggest a putative increased efficiency of 34 the use of Metformin in the first stages of CRC than in advanced disease.
Introduction
46
Colorectal cancer (CRC) is the third most common cancer in men (10% of the total), after lung and prostate cancer, and the second in women (9.2% of the total), after breast cancer [1] . Most of 70 robust anti-proliferative effect on several types of cancer such as colon, pancreatic, breast, 71 ovarian, prostate and lung cancer cells [6] . Furthermore, Metformin has been recently associated 72 with improved survival of cancer patients, including CRC, though its use as an antitumoral agent 73 has not been established yet [7] 74
The ACSL/SCD axis pro-tumorigenic activity has been also described to be post-transcriptionally 75 regulated by miRNAs. miR-544a, miR-142, and miR-19b-1 has been proposed as major 76 regulators of the ACSL/SCD network and the miR-19b-1-3p isoform decreased expression 77 associated with a poorer survival rate in CRC patients, consistently with ACSL/SCD involvement 78 in patients relapse [8] .
79
To get insight into the metabolic implication on CRC progression with a special focus on the 80 ACSL/SCD axis and the effect of metformin in each case, more personalized and physiological 81 tools are needed since most of the available data rely on traditional studies using cancer cell lines 82 cultures. In this way, the organoid culture system opens a new methodological door for ex vivo 83 studies.
84
Adult tissue-derived epithelial organoids, also called "mini guts" 
133
Drugs treatment -viability assays 134 Cell viability was determined by counting and seeding 1000 crypts in 60% of Matrigel in 48-well 135 plates. After 2 days of culture, organoids were exposed 48 hours to 10 µM Metformin (Sigma) or 136 10, 100 or 150 µM 5-FU (Sigma) in supplemented ADF +++ media, as indicated in the figures.
137
At this point, organoids were collected, split and reseeded for recovery experiments over 72 hours 138 in supplemented ADF +++ media.
139
Upon treatments (48h) or recovery assays (post-72h), organoids were incubated 3 hours with 3-
140
(4,5-dimethyl-thyazol-2-yl)-2,5-diphenyl-tetrazolium (MTT, Sigma). After discarding the media, 
Results
179
ACSL4 is overexpressed throughout CRC-like organoids 180 stages 181 ACSL4 has been previously reported to be overexpressed in malignant tumors, and together with 182 ACSL1 and SCD form an axis involved in CRC progression. ACSL1, ACSL4, and SCD mRNA 183 expression was measured in CRC-like organoids. ACSL4 mRNA was very significantly 184 augmented in more aggressive stages compared to WT ( Fig 1A) . It is shown an intermediate 185 expression pattern in Apc-mutated organoids, with a significantly differential expression (p-186 value: **) compared to the following second stage (Apc, Kras mutated stage) henceforth.
187
Conversely, ACSL1 and SCD levels were maintained or increased from the third stage henceforth, Interestingly, organoids in more advanced stages (III and IV) presented a genetic misbalance in 196 ACSL4 expression ( Fig 1A) with huge differences in their fold inductions ranges in the same 197 stage, though with a similar tendency.
MiR-19b-1-3p keeps its protective role in CRC-like organoids
201 prognosis in CRC patients (which might have a putative high clinical interest due to its potential 202 to be assed in plasma as a non-invasive biomarker); very likely through its involvement in cell 203 invasion and lipid metabolism regulation [8]. In the case of CRC-like organoids, this tendency 204 was maintained and miR-19b-1-3p expression was decreased in a stage-dependent manner ( Fig   205  1B) .
206
Together with miR-19b-1-3p, miR-142 (3p and 5p isoforms) and miR-544a (without murine 207 isoform) were also involved on targeting ACSL/SCD axis [8] . Hence, the previous mentioned 208 miRs plus miR-19b-1-5p isoform was measured though no statistically significant differences 216 we wondered what this drug effect would be through the different stages in tumor progression.
217
CRC-like organoids were treated with PBS, 10 µM of Metformin or with the commonly used 218 chemotherapeutic agent 5-FU; and the organoids viability was examined by MTT assays 48 hours 219 upon treatment. None of the drugs affected significantly the viability of WT organoids (Fig 2A) , 220 while they were able to cause a decrease of about 50% in the viability of mutated organoids 221 corresponding to the most aggressive phenotypes ( Fig 2B-E) . 5-FU higher concentrations (100 222 µM and 150 µM) showed the same effects than the lower concentration (10 µM) in mutated 223 organoids, while they had stronger effects on WT ones (S3A-E Figs). was quite significant reduced (p-value: ***) ( Fig 3A) . In Apc mutated organoids the recovery is 244 very significantly lower upon Metformin treatment (p-value: ****) than 5-FU (p-value: *), 245 compared to PBS recovery control; making these Apc mutated organoids the most responsive to 246 the Metformin treatment compared to 5-FU ( Fig 3B) . Regarding organoids corresponding to 247 stages II-III ( Figs 3C and D) , both treatments presented almost similar recovery effects, while in 248 stage IV organoids, 5-FU presented a stronger effect shown by the lower recovery of these 5-FU 249 treated organoids ( Fig 3E) . Again 5-FU higher concentrations (100 µM and 150 µM) had nearly 
264
Since WT organoids require more time to achieve their size and their crypt-like phenotype (Fig   265  3F) , the recovery measures are lesser than the mutated organoids. On the other hand, WT 266 organoids recovered upon Metformin treatment presented a higher size than the ones treated with 267 5-FU ( Fig 3F) . On the contrary, stage I (Apc mutated) organoids recovered upon Met treatment 268 showed an evident reduced size compared with the control and the 5-FU treated ones. In 269 accordance with viability assays results, this effect is lost in further stages; where Metformin is 270 less effective and Metformin treated recovered organoids presented a bigger size than the ones 271 treated with 5-FU.
272
By way of clarification, all mutated organoids presented Apc mutated since is the first gene in the 273 adenocarcinoma sequence. Apc completed deletion provokes a hyperactive Wnt signaling. This
Metformin action is stronger on ACSL4 and SCD
277 overexpressing first stages organoids 278 Since stage I organoids seemed to present a differential sensitivity to metformin compared to 279 other stages, together with a differential expression of ACSL4, we aimed to analyze the possible 280 link between Metformin and ACSL/SCD axis in intestinal organoids.
281
To this aim, ACSL4 expression was measured, as well as the other enzymes of the ACSL/SCD 282 metabolic network (ACSL1 and SCD) upon 10 µM Metformin treatment. ACSL4 mRNA 283 expression was strongly reduced by this drug compared to their non-treated controls in stage I and 284 II organoids. By contrast, stage III and IV presented no significance in their reduction or a slight 285 significance, respectively. WT organoids also presented a slight reduction of ACSL4 mRNA upon
286
Metformin treatment ( Fig 4B) . In addition, SCD expression levels were clearly decreased by
287
Metformin in WT and stage I organoids, while a less marked tendency was found for stage III 288 and IV organoids ( Fig 4C) . ACSL1 mRNA analysis showed less significant results ( Fig 4A) upon
289
Metformin treatment. 
299
The expression of these enzymes was also measured upon 10 µM 5-FU treatment. This drug was differences were showed between the effects in initial and later stages such as the case for
302
Metformin treatment (S5A-C Figs).
303
Metformin, but not 5-FU, downregulates stem cell biomarker
304
LGR5 and Wnt target genes expression in all organoid stages 305 To further assay whether Metformin treatment was targeting the organoids crypts stem cell 306 marker, LGR5; we analyzed its expression together with two other Wnt target genes, Axin2 and 307 Ctnnb-1. Importantly, LGR5 expression was significantly diminished in the whole CRC-like 308 organoids series upon Metformin treatment ( Fig 4C) as well as Axin-2 ( Fig 4D) and Ctnnb-1 (Fig   309  4E ) mRNAs. Surprisingly, this pattern was not maintained when organoids were treated with 10 310 µM 5-FU (S5D-F Figs).
311
Metformin action in CRC-like organoids is not related to a 312
Warburg-effect impairement 313 The avidity to perform glycolysis even in the presence of oxygen, known as the Warburg effect, . Therefore, we propose this system to get insight into 334 cancer progression mechanisms in regards to fatty acid metabolism and therefore, to assay 335 ACSL/SCD protumorigenic axis action in CRC.
336
We showed that ACSL4 augmented while miR-19b- organoids with the acquired CRC most common mutations (Fig 1A) , indicating a predominant 359 role of this ACSL/SCD component in these cancer progression aspects. The ACSL4 mRNA huge 360 range of expression considering the most mutated stages ( Fig 1A) could be explained since stages 361 III and IV in real tumors present an uncontrolled genetic variability with the accumulation of 362 other undetermined mutations. Organoids would be mimicking these uncontrolled stages,
363
compared to the homogeneity presented in 2D cultures. Conversely, ACSL1 static role (S1A Fig)   364 could be due to a lesser implication in tumor development in this system which can be also 365 explained by the fact that the rodent protein is one residue longer (699 amino acids) than the 366 human protein (698 amino acids), making it necessary to study the extent of this dissimilarity.
367
For its part, SCD overexpression has been mainly reported in mesenchymal tissues, rather than 368 epithelial ones, which are the only scaffold for organoids [32,33] giving a reason for the 369 distinctive results found in these epithelial systems among the first stages (S1B Fig) . 
380
Since Metformin was able to revert the ACSL/SCD EMT phenotype, we tried to gain insight on 381 this process using organoid cultures resembling the different stages of a CRC progression.
382
Metformin treatment seems to be more efficient than 5-FU only during first tumor stages, making 383 organoids recovery harder compared to the ones treated with 5-FU. We propose that Metformin 384 therapies could be an appealing alternative in those cases when the tumor is detected in very early 385 stages rather than 5-FU treatments. However, some studies of Metformin treatment in CRC 386 patients points to stage III to be the most likeable to present an effect [38] . Since CRC is very 387 improbable to detect on its very early stages, known as one of the most silent and deadly cancer;
388
we wonder whether these studies with a low number of candidates in stage I are enough 389 representative.
390
As well, Metformin therapies has been proposed alone or in combination with other drugs, in 
397
Previous reports hypothesized that the inhibition of mitochondrial complex I was the main 398 mechanism of action for Metformin. However, recent studies suggest that cancer progression is 399 compromised upon Metformin treatment, by decreasing the TCA cycle´s anaplerosis. Metformin 400 decreases the flow of glucose-and glutamine-derived metabolic intermediates into the TCA cycle, 404 downregulation in the presence of Metformin is clearly evident and the results are larger 405 significant in first stages (I, II) ( Fig 4A) . Maybe, the reduced overexpression of ACSL4 in the 406 first stages ( Fig 1A) increases the sensitivity to Metformin action ( Fig 4A) ; while in more 407 advanced stages, the overexpression is so high that Metformin action could appear to be less 408 effective. This would not be the case for SCD, which showed no overexpression in the first stages 409 and enhanced overexpression in III and IV stages, though it is significantly reduced upon
410
Metformin exposure again in the first stages ( Fig 4B) . On the other hand, it has been reported that 411 variations in the types and amounts of fatty acids, are able to modify intracellular ACSLs 
